NCT07154706 2026-02-11
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.
Phase 3 Recruiting
Nuvation Bio Inc.
Nuvation Bio Inc.
Nuvation Bio Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.